What is management review in GMP?

Short answer

Management review in GMP is the formal process through which senior management evaluates whether the Pharmaceutical Quality System remains suitable and effective. It should turn quality information into documented decisions about risk, priorities, resources, improvement and escalation.

A useful review does more than present event counts. It considers what the data mean, whether controls and actions are effective, where adverse trends are emerging and whether the organisation has the capacity to maintain a state of control.

Regulatory guidance and the ICH Q10 model

EU GMP Chapter 1 is regulatory guidance and places ultimate responsibility for an effective Pharmaceutical Quality System with senior management. It also expects periodic management review with senior-management involvement.

ICH Q10 describes a broader pharmaceutical quality-system model, including management review of process performance, product quality and the quality system itself. ICH Q10 explains that content additional to regional GMP requirements is optional, so it should not be presented as though every detail creates a separate legal requirement.

What management review should consider

The scope and frequency should reflect the size, complexity and risk profile of the organisation. Relevant inputs commonly include:

Progress against quality policy, objectives and performance indicators.

Process performance, product-quality monitoring and periodic quality reviews.

Complaints, recalls, deviations, CAPA and change-management performance.

Audit, self-inspection and regulatory-inspection outcomes.

Performance of outsourced activities and suppliers.

Data-integrity, validation, contamination-control and compliance risks.

Previous review actions, overdue commitments and recurring events.

Resource, competence, training, facility and system needs.

Relevant changes in regulation, guidance, products or business conditions.

Evidence of an effective review normally includes

A defined purpose, scope, frequency and senior owner.

Reliable inputs with meaningful trends rather than unexamined totals.

Attendance and contribution from the functions needed to make decisions.

Recorded challenge, risk assessment, decisions and escalation.

Actions with owners, priorities and realistic target dates.

Follow-up showing whether earlier decisions were implemented and effective.

Timely communication of outcomes to the appropriate levels of the organisation.

Common weaknesses

Treating management review as a presentation meeting rather than a governance process.

Reporting metrics without thresholds, trends, interpretation or decisions.

Excluding recurring deviations, overdue CAPA or resource constraints.

Closing actions administratively without confirming the intended outcome.

Failing to escalate patient, product, compliance or data-integrity risk.

Holding reviews but retaining no defensible record of decisions and follow-up.

Questions to ask internally

Does senior management receive information that supports timely decisions?

Are adverse trends and repeat events visible across systems and departments?

Are resource decisions linked to quality risk?

Can actions from previous reviews be traced to implementation and outcome?

Would the records demonstrate active senior-management oversight during an inspection?

How W2 can help

W2 Cleanroom Consulting can review management-review governance, challenge the quality and interpretation of performance information, and help organisations connect management oversight to contamination control, validation, inspection readiness and remediation. The client remains responsible for senior-management decisions, Quality approval and regulatory obligations.

Need to strengthen management review or PQS oversight?

Contact W2 Cleanroom Consulting at info@w2cleanrooms.com to discuss an independent review or improvement plan.

Prepared and reviewed by: W2 Cleanroom Consulting GMP team. Last reviewed: 24 July 2026.